Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.
Spelman T, Herring WL, Acosta C, Hyde R, Jokubaitis VG, Pucci E, Lugaresi A, Laureys G, Havrdova EK, Horakova D, Izquierdo G, Eichau S, Ozakbas S, Alroughani R, Kalincik T, Duquette P, Girard M, Petersen T, Patti F, Csepany T, Granella F, Grand'Maison F, Ferraro D, Karabudak R, Jose Sa M, Trojano M, van Pesch V, Van Wijmeersch B, Cartechini E, McCombe P, Gerlach O, Spitaleri D, Rozsa C, Hodgkinson S, Bergamaschi R, Gouider R, Soysal A, Castillo-Triviño, Prevost J, Garber J, de Gans K, Ampapa R, Simo M, Sanchez-Menoyo JL, Iuliano G, Sas A, van der Walt A, John N, Gray O, Hughes S, De Luca G, Onofrj M, Buzzard K, Skibina O, Terzi M, Slee M, Solaro C, Oreja-Guevara, Ramo-Tello C, Fragoso Y, Shaygannejad V, Moore F, Rajda C, Aguera Morales E, Butzkueven H. Spelman T, et al. Among authors: butzkueven h. J Med Econ. 2024 Jan-Dec;27(1):109-125. doi: 10.1080/13696998.2023.2293379. Epub 2023 Dec 26. J Med Econ. 2024. PMID: 38085684 Free article.
Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Van Der Walt A, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Blanco Morgado Y, Spitaleri D, van Pesch V, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H. Spelman T, et al. Among authors: butzkueven h. Mult Scler. 2023 Feb;29(2):221-235. doi: 10.1177/13524585221137502. Epub 2022 Nov 26. Mult Scler. 2023. PMID: 36433775 Free PMC article.
Switching to natalizumab or fingolimod in multiple sclerosis: Comparative effectiveness and effect of pre-switch disease activity.
Spelman T, Horakova D, Ozakbas S, Alroughani R, Onofrj M, Kalincik T, Prat A, Terzi M, Grammond P, Patti F, Csepany T, Boz C, Lechner-Scott J, Granella F, Grand'Maison F, van der Walt A, Zhu C, Butzkueven H; MSBase Study Group. Spelman T, et al. Among authors: butzkueven h. Mult Scler Relat Disord. 2023 Feb;70:104477. doi: 10.1016/j.msard.2022.104477. Epub 2022 Dec 23. Mult Scler Relat Disord. 2023. PMID: 36746088 Free article.
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers.
Forsberg L, Spelman T, Klyve P, Manouchehrinia A, Ramanujam R, Mouresan E, Drahota J, Horakova D, Joensen H, Pontieri L, Magyari M, Ellenberger D, Stahmann A, Rodgers J, Witts J, Middleton R, Nicholas R, Bezlyak V, Adlard N, Hach T, Lines C, Vukusic S, Soilu-Hänninen M, van der Walt A, Butzkueven H, Iaffaldano P, Trojano M, Glaser A, Hillert J; SPMS Research Collaboration Network. Forsberg L, et al. Among authors: butzkueven h. Mult Scler J Exp Transl Clin. 2023 Feb 16;9(1):20552173231153557. doi: 10.1177/20552173231153557. eCollection 2023 Jan-Mar. Mult Scler J Exp Transl Clin. 2023. PMID: 36816812 Free PMC article.
A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Der Walt AV, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Morgado YB, Spitaleri D, Pesch VV, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H; MSBase Study Group. Spelman T, et al. Among authors: butzkueven h. Neurodegener Dis Manag. 2023 Aug;13(4):215-221. doi: 10.2217/nmt-2023-0005. Epub 2023 Jun 7. Neurodegener Dis Manag. 2023. PMID: 37287269 Review.
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
Li Y, Saul A, Taylor B, Ponsonby AL, Simpson-Yap S, Blizzard L, Broadley S, Lechner-Scott J; Ausimmune/AusLong Investigators Group; Karabudak R, Patti F, Eichau S, Onofrj M, Ozakbas S, Horakova D, Kubala Havrdova E, Grand'Maison F, Alroughani R, Gerlach O, Amato MP, Altintas A, Girard M, Duquette P, Blanco Y, Ramo-Tello C, Laureys G, Kalincik T, Khoury SJ, Shaygannejad V, Etemadifar M, Singhal B, Mrabet S, Foschi M, Habek M, John N, Hughes S, McCombe P, Ampapa R, van der Walt A, Butzkueven H, de Gans K, McGuigan C, Oreja-Guevara C, Sa MJ, Petersen T, Al-Harbi T, Sempere AP, Van Wijmeersch B, Grigoriadis N, Prevost J, Gray O, Castillo-Triviño T, Macdonell R, Lugaresi A, Sajedi SA; MSBase; van der Mei I. Li Y, et al. Among authors: butzkueven h. J Neurol. 2024 Jan;271(1):472-485. doi: 10.1007/s00415-023-11980-z. Epub 2023 Sep 28. J Neurol. 2024. PMID: 37768389 Free PMC article.
Language impairments in seropositive and seronegative autoimmune encephalitis.
Griffith SP, Wesselingh R, D'Aprano F, Seery N, Rushen T, Kyndt C, Long B, Seneviratne U, Kalincik T, Buzzard K, Butzkueven H, O'Brien TJ, Alpitsis R, Malpas CB, Monif M; Australian Autoimmune Encephalitis Consortium. Griffith SP, et al. Among authors: butzkueven h. Neurol Sci. 2024 Feb 15. doi: 10.1007/s10072-024-07382-2. Online ahead of print. Neurol Sci. 2024. PMID: 38358549
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.
Ryerson LZ, Foley JF, Defer G, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Sinks S, Kuhelj R, Bodhinathan K, Lasky T. Ryerson LZ, et al. Among authors: butzkueven h. Mult Scler Relat Disord. 2023 Apr;72:104561. doi: 10.1016/j.msard.2023.104561. Epub 2023 Feb 11. Mult Scler Relat Disord. 2023. PMID: 36931078 Free article. Clinical Trial.
375 results